PDS Biotechnology Corporation (NASDAQ:PDSB) Financings

PDS Biotechnology Corporation

Financings

RaiseDate
Warrant exercise of common stock warrants (common stock or pre-funded warrants)
Closed: US$3.9M raised · US$0.22 a share
Buyers: NantWorks (exercised warrants to purchase an aggregate of 17,699,115 shares (or pre-funded warrants in lieu thereof))
Use of proceeds: Advance PDS0301 toward a Phase 3 trial in metastatic colorectal cancer, PDS0101 partnership strategy and general corporate purposes
Nov 10, 2026
Private placement of units of common stock or pre-funded warrants with common warrants
Tranche closed: US$11.3M raised · US$0.2825 a unit · a Common Warrant to purchase one-half of one Private Placement Share
Buyers: Nant Capital, LLC (Led the round; obligated to purchase $10,000,000 at the Milestone Closing); AB Group Ltd. (Obligated to purchase $1,000,000 at the Milestone Closing)
Use of proceeds: Repay outstanding indebtedness, working capital and general corporate purposes, including clinical development, R&D and G&A expenses
Sep 14, 2026
Registered direct offering of shares of common stock (or pre-funded warrants) and accompanying warrants
Announced: about US$5.3M · US$0.91 a share · Warrants at US$1 for 60 months · Craig-Hallum
Dealers: Craig-Hallum (lead)
Use of proceeds: Continuation of the VERSATILE-003 Phase 3 trial, other research and development and general corporate purposes
Nov 11, 2025
Registered direct offering of shares of common stock (or common stock equivalents) and warrants
Announced: about US$11M · US$1.5 a share · Warrants at US$1.5 for 60 months · A.G.P./Alliance Global Partners
Dealers: A.G.P./Alliance Global Partners (lead)
Insiders: Certain directors of the Company participate at a combined purchase price of $1.66
Use of proceeds: Research and development expenses and general corporate purposes
Feb 27, 2025

Read by 6ix AI from the company's releases